Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to $34.6 million.

  • Neurocrine Biosciences' Other Operating Expenses rose 18130.08% to $34.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $69.5 million, marking a year-over-year increase of 4946.24%. This contributed to the annual value of $69.5 million for FY2025, which is 4946.24% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Other Operating Expenses is $34.6 million, which was up 18130.08% from $14.3 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Other Operating Expenses peaked at $152.4 million during Q1 2023, and registered a low of $2.9 million during Q1 2021.
  • Its 4-year average for Other Operating Expenses is $21.0 million, with a median of $11.3 million in 2025.
  • In the last 5 years, Neurocrine Biosciences' Other Operating Expenses tumbled by 9653.47% in 2021 and then soared by 18130.08% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Other Operating Expenses (Quarter) stood at $4.2 million in 2021, then soared by 102.38% to $8.5 million in 2023, then soared by 44.71% to $12.3 million in 2024, then surged by 181.3% to $34.6 million in 2025.
  • Its Other Operating Expenses was $34.6 million in Q4 2025, compared to $14.3 million in Q3 2025 and $11.3 million in Q2 2025.